* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download pharmacokinetics
Survey
Document related concepts
Discovery and development of HIV-protease inhibitors wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Theralizumab wikipedia , lookup
Transcript
PHARMACOKINETICS: HIV DRUGS ALLIE PUNKE ([email protected]) RENAL FUNCTION • Patients with HIV are at an increased risk of having nephropathy that can lead to ESRD • DJ is a Caucasian female who was just diagnosed with HIV. When/should you recommend for her to be screened for renal function? • What are you specifically screening for when performing renal function tests? RENAL FUNCTION • CG is a HIV+ (diagnosed about a year ago) African American male. At your appointment with him today, he tells you he sometimes forgets to take his medications for HIV. The CD4 and HIV RNA count today is 150 and 900, respectively. His renal function was stable when he was diagnosed with HIV. Should we check his renal function today? RENAL FUNCTION • When to screen patients for renal function: • Screen ALL patients when they are diagnosed with HIV • Yearly screening if patients are at high risk • • • • African American CD4<200 HIV RNA>400 Family history of renal problems HEPATIC FUNCTION • What makes HIV + patients at increased risk for liver function abnormalities? HEPATIC FUNCTION • GP is a 28 YO AA male who was just diagnosed with HIV. How often should we monitor his hepatic function? DOSE ADJUSTMENTS • Patients with renal or hepatic issues will most likely: • Not be able to take medications that are _________. • Will often require _________ doses • Will be advised to take medications _________ HD session. • Will or will not require trough concentrations. DOSE ADJUSTMENTS • 1. INST: • General dose adjustments: • Renal • Hepatic • Dolutegravir (DTG) Trivicay: • Elvitegravir (EVG) Vitekta: • Genvoya (Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide): • Stribild (Elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate) DOSE ADJUSTMENTS • 2. NNRTI: • General dose adjustments: • Renal • Hepatic • Efavirenz (EFV) Sustiva DOSE ADJUSTMENTS • 3. PI • General dose adjustments: • Renal • Hepatic • Darunavir + cobicistat • 4. NRTI • General dose adjustments: • Renal • Hepatic • • • • • Abacavir Emtricitabine Lamivudine Tenofovir disoproxil fumarate Truvada (tenofovir disoproxil fumarate/emtricitabine) DOSE ADJUSTMENTS • In general, patients with renal/hepatic issues should avoid co-formulated products; however, name two combination products that have lower renal cut-off that may allow patients to continue until renal dysfunction becomes worse: DOSE ADJUSTMENTS • T/F: Emtricitabine is a member of the NNRTI class, which generally does not require renal dose adjustment. • T/F: Atripla does not require dose adjustment for patients with decreased renal function. • T/F: Stribild can be recommended without testing renal function when initiating, but yearly renal function screening is recommended. DRUG MONITORING • T/F: Most patients with HIV receiving antiretroviral medication should have their medications monitored through the use of drug concentrations • T/F: Patients who do have their HIV medications monitored experience quicker time to undetectable RNA load and less side effects • T/F: Monitoring HIV medications is recommended in HIV guidelines due to clinical trials showing that monitoring improves clinical outcomes PATIENT CASE • A patient who was recently diagnosed with HIV has been on anti-retroviral therapy for the past 3 months. She reports being extremely adherent (the pill counts also show she has been adherent). However, her CD4 count is still very low and her RNA is quite high. What can we consider doing? PRE/POST EXPOSURE PROPHYLAXIS • PEP: • Start when: • Stop when: • Drug: • nPEP: • Substantial vs negligible risk: • Drug: • PrEP: • Drug: PRE-EXPOSURE PROPHYLAXIS • If you start a patient on Truvada, when would you want to schedule a follow up visit? • What are some things to monitor for a patient receiving pre-exposure prophylaxis? • If a patient becomes HIV + while on prophylaxis (and the diagnosis is confirmed and CD4 count is ordered), what could you consider doing? PRE-EXPOSURE PROPHYLAXIS • For all groups (MSM, heterosexuals, IVDU)…what must we make sure they do NOT have before initiating HIV pre-exposure prophylaxis? PRE-EXPOSURE PROPHYLAXIS SUMMARY • Recognize the need to monitor for renal and hepatic function in HIV + patients • Recognize the classes of medications as well as the combination products that generally need to be adjusted for renal or hepatic function • Know the drug used for pre and pre-exposure prophylaxis QUESTIONS?